Cohance Lifesciences Limited — Important, 25-04-2025: General Updates

Suven Pharmaceuticals Limited has provided updates on the Scheme of Amalgamation with Cohance Lifesciences Limited. The Board of Directors has approved the effective date of the amalgamation as May 1, 2025. This marks a significant step in the integration process, following the approval from the National Company Law Tribunal.

Additionally, the record date for the allotment of shares has been set for May 8, 2025. Shareholders of Cohance Lifesciences will receive 11 fully paid-up equity shares of Suven Pharmaceuticals for every 295 shares held in Cohance, strengthening the company's equity structure. This merger is anticipated to enhance Suven's operational capabilities and market presence, presenting positive developments for investors.